Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: An interaction study in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 65, Issue 10, 2009, Pages 999-1006

  Corti, Natascia ^a   Heck, Antje ^a   Rentsch, Katharina ^a   Zingg, Walter ^b   Jetter, Alexander ^a   Stieger, Bruno ^a   Pauli Magnus, Christiane ^a,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Albendazole; Benzimidazoles; Drug interaction; Mebendazole; Ritonavir

Indexed keywords

ALBENDAZOLE; MEBENDAZOLE; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION;

ADULT; ALBENDAZOLE; ANTI-HIV AGENTS; ANTIPARASITIC AGENTS; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MEBENDAZOLE; MIDDLE AGED; REFERENCE VALUES; RITONAVIR; TIME FACTORS;

EID: 70349246420     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0683-y     Document Type: Article

References (27)

1. RW Ammann J Eckert 1996 Cestodes. Echinococcus Gastroenterol Clin North Am 25 3 655 689 8863045 10.1016/S0889-8553(05)70268-5 1:STN:280: DyaK2s%2Fhs1Cisg%3D%3D (Pubitemid 26335828)
2. MC Hosseinipour S Napravnik G Joaki S Gama N Mbeye B Banda F Martinson I Hoffman MS Cohen 2007 HIV and parasitic infection and the effect of treatment among adult outpatients in Malawi J Infect Dis 195 9 1278 1282 17396996 10.1086/513274 (Pubitemid 46649612)
3. W Zingg EC Renner-Schneiter C Pauli-Magnus EL Renner J van Overbeck E Schlapfer M Weber R Weber M Opravil B Gottstein RF Speck 2004 Alveolar echinococcosis of the liver in an adult with human immunodeficiency virus type-1 infection Infection 32 5 299 302 15624896 10.1007/s15010-004-3134-9 1:STN:280:DC%2BD2cnkvVaitA%3D%3D (Pubitemid 39319149)
4. SE Marriner DL Morris B Dickson JA Bogan 1986 Pharmacokinetics of albendazole in man Eur J Clin Pharmacol 30 6 705 708 3770064 10.1007/BF00608219 1:CAS:528:DyaL28XmtFyhsb8%3D
5. M Dawson RJ Allan TR Watson 1982 The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole Br J Clin Pharmacol 14 3 453 455 7126419 1:CAS:528:DyaL38XmtVOlt7g%3D (Pubitemid 13139149)
6. C Villaverde AI Alvarez P Redondo J Voces JL Del Estal JG Prieto 1995 Small intestinal sulphoxidation of albendazole Xenobiotica 25 5 433 441 7571717 10.3109/00498259509061863 1:CAS:528:DyaK2MXmsFCjsbw%3D
7. HC Rawden GO Kokwaro SA Ward G Edwards 2000 Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes Br J Clin Pharmacol 49 4 313 322 10759686 10.1046/j.1365-2125.2000.00170.x 1:CAS:528:DC%2BD3cXjtl2hsb8%3D (Pubitemid 30195273)
8. H Souhaili-El Amri O Mothe M Totis C Masson AM Batt P Delatour G Siest 1988 Albendazole sulfonation by rat liver cytochrome P-450c J Pharmacol Exp Ther 246 2 758 764 3404457 1:CAS:528:DyaL1cXlt1WqtLc%3D
9. G Merino AJ Molina JL Garcia MM Pulido JG Prieto AI Alvarez 2003 Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors Int J Pharm 263 1-2 123 132 12954187 10.1016/S0378-5173(03)00369-7 1:CAS:528:DC%2BD3sXmvValtLs%3D (Pubitemid 37087939)
10. A Bekhti J Pirotte 1987 Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts Br J Clin Pharmacol 24 3 390 392 3663452 1:STN:280:DyaL1c%2FisVKksA%3D%3D
11. DW Gottschall VJ Theodorides R Wang 1990 The metabolism of benzimidazole anthelmintics Parasitol Today 6 4 115 124 15463313 10.1016/0169-4758(90)90228-V 1:CAS:528:DyaK3cXksFWru7g%3D (Pubitemid 20131120)
12. PJ Luder B Siffert F Witassek F Meister J Bircher 1986 Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions Eur J Clin Pharmacol 31 4 443 448 3816925 10.1007/BF00613522 1:STN:280:DyaL2s7jtlOqsA%3D%3D (Pubitemid 17018784)
13. CS Ernest 2nd SD Hall DR Jones 2005 Mechanism-based inactivation of CYP3A by HIV protease inhibitors J Pharmacol Exp Ther 312 2 583 591 15523003 10.1124/jpet.104.075416 1:CAS:528:DC%2BD2MXhsVCnsb0%3D (Pubitemid 40189555)
14. KE Culm-Merdek LL von Moltke L Gan KA Horan R Reynolds JS Harmatz MH Court DJ Greenblatt 2006 Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir Clin Pharmacol Ther 79 3 243 254 16513448 10.1016/j.clpt.2005.11.009 1:CAS:528: DC%2BD28XitVKhurg%3D (Pubitemid 43297016)
15. V Dixit N Hariparsad F Li P Desai KE Thummel JD Unadkat 2007 Cytochrome P450 enzymes and transporters induced by anti-HIV protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions Drug Metab Dispos 35 1853 1859 17639026 10.1124/dmd.107.016089 1:CAS:528:DC%2BD2sXhtFansbbL (Pubitemid 47481578)
16. RF Yeh VE Gaver KB Patterson NL Rezk F Baxter-Meheux MJ Blake JJ Eron Jr CE Klein JC Rublein AD Kashuba 2006 Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers J Acquir Immune Defic Syndr 42 1 52 60 16639344 1:CAS:528:DC%2BD28XlsFGqtrY%3D
17. C Wyen U Fuhr D Frank R Aarnoutse T Klaasen A Lazar A Seeringer O Doroshyenko J Kirchheiner F Abdulrazik N Schmeisser C Lehmann W Hein E Schomig D Burger G Fatkenheuer A Jetter 2008 Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients Clin Pharmacol Ther 84 75 82 18183034 10.1038/sj.clpt.6100452 1:CAS:528:DC%2BD1cXnt1Kqs7c%3D (Pubitemid 351861487)
18. A Mirfazaelian S Dadashzadeh MR Rouini 2002 Effect of gender in the disposition of albendazole metabolites in humans Eur J Clin Pharmacol 58 6 403 408 12242599 10.1007/s00228-002-0488-8 1:CAS:528:DC%2BD38XntFensb0%3D
19. A Hsu GR Granneman G Witt C Locke J Denissen A Molla J Valdes J Smith K Erdman N Lyons P Niu JP Decourt JB Fourtillan J Girault JM Leonard 1997 Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects Antimicrob Agents Chemother 41 5 898 905 9145841 1:CAS:528:DyaK2sXjtVCnt7Y%3D
20. CJ Fichtenbaum JG Gerber SL Rosenkranz Y Segal JA Aberg T Blaschke B Alston F Fang B Kosel F Aweeka 2002 Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 Aids 16 4 569 577 11873000 10.1097/00002030-200203080-00008 1:CAS:528:DC%2BD38XivVyhsrs%3D (Pubitemid 34218852)
21. FDA (2006) Guidance for industry. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. FDA, Washington DC
22. XQ Li A Bjorkman TB Andersson LL Gustafsson CM Masimirembwa 2003 Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data Eur J Clin Pharmacol 59 5-6 429 442 12920490 10.1007/s00228-003-0636-9 1:CAS:528: DC%2BD3sXnt1KitrY%3D (Pubitemid 37214951)
23. G Merino JW Jonker E Wagenaar MM Pulido AJ Molina AI Alvarez AH Schinkel 2005 Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2) Drug Metab Dispos 33 5 614 618 15703302 10.1124/dmd.104.003319 1:CAS:528:DC%2BD2MXkt1Cmtrc%3D (Pubitemid 40593873)
24. MM Foisy EM Yakiwchuk CA Hughes 2008 Induction effects of ritonavir: implications for drug interactions Ann Pharmacother 42 7 1048 1059 18577765 10.1345/aph.1K615 1:CAS:528:DC%2BD1cXps1GqsLk%3D
25. CM Smith SR Faucette H Wang EL LeCluyse 2005 Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers J Biochem Mol Toxicol 19 2 96 108 15849716 10.1002/jbt.20058 1:CAS:528:DC%2BD2MXjvFSlurw%3D (Pubitemid 40571690)
26. MJ van der Lee L Dawood HJ ter Hofstede MJ de Graaff-Teulen EW van Ewijk-Beneken Kolmer N Caliskan-Yassen PP Koopmans DM Burger 2006 Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects Clin Pharmacol Ther 80 2 159 168 16890577 10.1016/j.clpt.2006.04.014 (Pubitemid 44160694)
27. HG Schipper RP Koopmans J Nagy JJ Butter PA Kager CJ Van Boxtel 2000 Effect of dose increase or cimetidine co-administration on albendazole bioavailability Am J Trop Med Hyg 63 5-6 270 273 11421376 1:CAS:528: DC%2BD3MXkvFeitb0%3D